Comparative Analysis of T1 and T2 Metrics in Prostate Cancer Bone Metastases
Overview
This prospective study evaluated magnetic resonance fingerprinting (MRF) against conventional MRI techniques for measuring T1 and T2 relaxation times in prostate cancer bone metastases before and after treatment. MRF demonstrated comparable reproducibility and the ability to detect treatment-induced changes efficiently, supporting its integration into clinical protocols.
Background
Prostate cancer frequently metastasizes to bone marrow, necessitating improved imaging biomarkers for early treatment response assessment. Conventional morphological imaging criteria exist but lack widely recognized quantitative response markers for metastatic bone disease. Magnetic resonance fingerprinting (MRF) offers rapid, co-registered quantitative maps of T1 and T2 relaxation times, potentially enhancing tumor biology characterization and treatment monitoring compared to standard MRI sequences.
Data Highlights
Parameter
Technique
Acquisition Time
Slices
Measurement Range
T1
MRF
1 min 50 s
3 slices
24–1879 ms (phantom)
T1
IR-TSE (Conventional)
10 min 55 s
1 slice
24–1879 ms (phantom)
T2
MRF
1 min 50 s
3 slices
8–1044 ms (phantom)
T2
DSE (Conventional)
2 min 36 s
1 slice
8–1044 ms (phantom)
Key Findings
MRF provides rapid acquisition of T1 and T2 maps covering multiple slices in under 2 minutes, compared to longer times for conventional sequences.
MRF measurements showed high repeatability and reproducibility in phantom studies across a wide range of T1 and T2 values relevant to bone metastases.
In patients with metastatic prostate cancer, MRF-derived T1 and T2 values were comparable to those obtained by conventional inversion recovery turbo spin echo and double spin echo sequences.
MRF detected treatment-induced changes in T1 and T2 relaxation times after an average of 3.4 months of therapy, demonstrating potential as an early response biomarker.
The ability of MRF to produce multiple co-registered quantitative maps efficiently supports its clinical integration for bone disease imaging and treatment assessment.
Clinical Implications
MRF offers a time-efficient and reproducible method for quantitative T1 and T2 mapping in prostate cancer bone metastases, facilitating early detection of treatment response. Its integration into clinical MRI protocols can enhance the assessment of metastatic bone disease without significantly extending scan times. This may improve personalized treatment monitoring and decision-making.
Conclusion
MRF is a promising quantitative imaging technique that matches conventional MRI in measuring T1 and T2 relaxation times while offering faster acquisition and multi-slice coverage. Its application in prostate cancer bone metastases supports its role in clinical treatment response evaluation.
References
Ma et al. 2013 -- Magnetic Resonance Fingerprinting
Various studies 2013-2022 -- Applications of MRF in oncology
NIST/ISMRM Phantom Documentation -- Test Object for T1 and T2 Calibration
by Mihaela Rata, Nina Tunariu, Yun Jiang, Julie Hughes, Georgina Hopkinson, Erica Scurr, Jessica M. Winfield, Vikas Gulani, Dow-Mu Koh, Matthew R. Orton
